Company intelligence / Profile preview

Suzhou Shang Enda Biotechnology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Suzhou Shang Enda Biotechnology is an active biotech/pharma company based in Suzhou, China, specializing in the development and commercialization of central nervous system therapeutics, particularly the opioid analgesic tapentadol (Palexia), which is a Schedule II opioid. The company holds a significant 28% share in the global Tapentadol market, driven by its R&D capabilities and demand from hospital-based prescriptions[8]. They are operational and engaged in commercial activities, offering both high-purity and low-purity forms of tapentadol tablets for pain management, and compete internationally in this market[9][10].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Suzhou Shang Enda Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Shang Enda Biotechnology.

Explore the full profile